Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27370728 | 0.82 | EPHX1 (0.39) | SLC6A2SLC6A3SLC6A4CTSC | |
| SCHEMBL22461896 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4CTSC | |
| SCHEMBL20833040 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4CTSC | |
| SCHEMBL22260324 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4CTSC | |
| SCHEMBL25339415 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4CTSC | |
| SCHEMBL6889303 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL6683095 | 0.75 | EPHX1 (0.38) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL6666146 | 0.75 | EPHX1 (0.38) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL6671579 | 0.75 | EPHX1 (0.38) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL6666144 | 0.75 | EPHX1 (0.38) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SLC6A2 3662/4885SLC6A3 2786/4885SLC6A4 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.